cefuroxime proxetil Tablet BP 250 mg

Cefpodoxime Proxetil Dispersible Tablet 200 mg is indicated for the treatment of the following infections when caused by susceptible pathogens in adults:
Upper Respiratory Tract Infections: Acute bacterial sinusitis, tonsillitis
Lower Respiratory Tract Infection: Acute exacerbation of chronic bronchitis, Bacterial pneumonia – Cefpodoxime might not be suitable option depending on the pathogen involved
Consideration should be given to the official guidance on the appropriate use of antibacterial agents.

Route of administration: oral.
The tablets should be taken with food for optimum absorption.
Adults and adolescents with normal renal function:
Upper respiratory tract infections: Acute bacterial sinusitis: 200 mg twice daily, Tonsillitis: 100 mg twice daily.
Lower respiratory tract infections: Acute exacerbation of chronic bronchitis: 200mg twice daily, Bacterial pneumonia: 200mg twice daily
Elderly:
It is not necessary to modify the dose in elderly patients with normal renal function.
Children:
Pediatric formulation of cefpodoxime is available for infants and children.

Gastric pressure, nausea, vomiting, abdominal pain, flatulence, diarrhoea. The possibility of pseudomembranous enterocolitis should be considered if severe or persistent diarrhoea occurs during or after treatment. Bloody diarrhoea can occur as a symptom of enterocolitis. Loss of appetite,

Cefpodoxime Proxetil Dispersible Tablet 200 mg is not a preferred antibiotic for the treatment of staphylococcal pneumonia and should not be used in the treatment of atypical pneumonia caused by organisms such as Legionella, Mycoplasma and Chlamydia. Cefpodoxime Proxetil Dispersible Tablet 200 mg is not recommended for the treatment of pneumonia due to S. pneumoniae.
As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefpodoxime must be discontinued immediately and adequate emergency measures must be initiated.
Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to Cefpodoxime Proxetil Dispersible Tablet 200 mg , to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefpodoxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.
In cases of severe renal insufficiency it may be necessary to reduce the dosage regimen dependent on the creatinine clearance.
Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all anti-bacterial agents, including cefpodoxime, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of cefpodoxime. Discontinuation of therapy with cefpodoxime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Cefpodoxime should always be prescribed with caution in patients with a history of gastrointestinal disease, particularly colitis.
As with all beta-lactam antibiotics, neutropenia and more rarely agranulocytosis may develop particularly during extended treatment. For cases of treatment lasting longer than 10 days, the blood count should be monitored and treatment discontinued if neutropenia is found.
Cephalosporins may be absorbed onto the surface of red cell membranes and react with antibodies directed against the drug. This can produce a positive Coomb’s test and very rarely, haemolytic anaemia. Cross-reactivity may occur with penicillin for this reaction.
Changes in renal function have been observed with cephalosporin antibiotics, particularly when given concurrently with potentially nephrotoxic drugs such as aminoglycosides and/or potential diuretics. In such cases, renal function should be monitored.
As with other antibiotics, prolonged use of cefpodoxime may result in the overgrowth of non-susceptible organisms (Candida and Clostridium difficile), which may require interruption of treatment.

Store below 30°C temperature and protect from light.
Keep the medicine out of reach of children.

Alu-Alu blister packs.
Cefpodoxime Proxetil Dispersible Tablet 200 mg is available in an Alu-Alu blister of 10 tablets. Such 01 blister in a mono carton with package insert and Such 10 mono carton in a unit box.